Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

ST-246 TREATMENT OF SMALLPOX VACCINE-RELATED ADVERSE EVENTS IN MURINE MODELS

Award Number: R43AI075747
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2007
PERIOD OF PERFORMANCE END DATE: 07/31/2009

Group Awards By:

View Award Description

ST-246 TREATMENT OF SMALLPOX VACCINE-RELATED ADVERSE EVENTS IN MURINE MODELS - DESCRIPTION (provided by applicant): The renewed threat of smallpox as a bioweapon and the emerging zoonotic threat of monkeypox highlight the need for effective poxvirus countermeasures. Use of the smallpox vaccine poses a serious health risk, especially for the immunocompromised, or those with eczema/atopic dermatitis. It is our long-term goal to establish a safe and effective vaccine regimen that includes the use of the currently approved, efficacious smallpox vaccine and an antiviral drug to prevent or treat adverse events particularly in the aforementioned high-risk populations. We hypothesize that co-administration of the smallpox vaccine and ST-246, an antiviral drug, to inhibit viral dissemination from the original site of inoculation, will significantly reduce vaccine-related pathologies in immunodeficient and eczematous hosts without compromising protective immunity elicited by the vaccine. Our hypothesis extends from previous observations: First, lethal poxvirus infections in humans and in animal models results from dissemination from the original site of inoculation and wide-spread systemic infection. Second, treatment of a normally lethal poxvirus infection, with ST-246, a drug that specifically blocks viral dissemination, is fully protective in numerous animal models. Third, we have completed pilot studies performed in immunocompetent mice, demonstrating that protective immunity elicited by the Dryvax(r) smallpox vaccine is in no way compromised by ST-246 and may in fact be enhanced. It remains to be seen whether ST-246 actually reduces the occurrence of vaccine-related adverse events. To evaluate whether ST-246 may improve the safety of the smallpox vaccine without compromising protective immunity, we propose to utilize murine models for immunodeficiency and eczema/atopic dermatitis as hosts for poxvirus challenge and ST-246 treatment. Toward this end, the following specific aims are proposed: 1. Evaluate the prophylactic and therapeutic efficacy of ST-246 in vaccinia-challenged murine models of B and T cell immunodeficiency. 2. Evaluate the prophylactic and therapeutic efficacy of ST-246 in vaccinia-challenged murine models of eczema/atopic dermatitis. 3. Analyze protective immune responses elicited by vaccination in combination with ST- 246 in immunodeficient and eczematous mice.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2008 ( Subtotal = $321,291 )
2008	2008	SIGA TECHNOLOGIES, INC	420 LEXINGTON AVENUE	NEW YORK	NY	10170	NEW YORK	USA	Allergy and Infectious Diseases Research	000	2	7/29/2008	NON-COMPETING CONTINUATION	$321,291
														Subtotal = $321,291

Issue Date FY: 2007 ( Subtotal = $293,399 )
2007	2007	SIGA TECHNOLOGIES, INC	4575 SW RESEARCH WAY SUITE 230	CORVALLIS	OR	97333	BENTON	USA	Allergy and Infectious Diseases Research	000	1	7/30/2007	NEW	$293,399
														Subtotal = $293,399

Grand Total All Awards = $614,690

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ST-246 TREATMENT OF SMALLPOX VACCINE-RELATED ADVERSE EVENTS IN MURINE MODELS

Award Number: R43AI075747

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2007

PERIOD OF PERFORMANCE END DATE: 07/31/2009

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer